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Background: Symptoms of heart failure with preserved left ventricular systolic function are common among
patients undergoing peritoneal dialysis (PD). Epicardial fat (EpF) is an ectopic fat depot with possible paracrine or
mechanical effects on myocardial function. The aim of our current study is to assess the association between EpF
and Left ventricular diastolic dysfunction (LVDD) in patients undergoing PD and to clarify the relationships among
EpF, inflammation, and LVDD in this population.
Methods: This was a cross-sectional study of 149 patients with preserved left ventricular systolic function who were
undergoing PD. LVDD was diagnosed (according to the European Society of Cardiology guidelines) and EpF
thickness measured by echocardiography. The patients without LVDD were used as controls. The serum
inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) was measured. The location and amount of
adipose tissue were assessed by computed tomography (CT) at the level of the fourth lumbar vertebra.
Results: Subjects with LVDD had higher levels of hsCRP, more visceral and peritoneal fat, and thicker EpF
(all p < 0.001) than controls. Visceral adipose tissue, hsCRP, and EpF all correlated significantly (p < 0.05) with LVDD.
Multivariate regression analysis rendered the relationship between visceral adipose tissue and LVDD insignificant,
whereas EpF was the most powerful determinant of LVDD (odds ratio = 2.41, 95% confidence interval = 1.43–4.08,
p < 0.01). EpF thickness also correlated significantly with the ratio of transmitral Doppler early filling velocity to
tissue Doppler early diastolic mitral annular velocity (E/e’; r = 0.27, p < 0.01).
Conclusion: EpF thickness is significantly independently associated with LVDD in patients undergoing PD and may
be involved in its pathogenesis.
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Cardiovascular disease (CVD) is the most common cause
of mortality and morbidity among patients with end-stage
renal disease (ESRD) undergoing either hemodialysis or
peritoneal dialysis (PD) [1]. Patients with ESRD are prone* Correspondence: chokaiwu@yahoo.com.tw
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reproduction in any medium, provided the orto hypertension and left ventricular hypertrophy (LVH),
which is a physiological response to pressure and volume
overload. They also suffer disproportionately from fluid
overload and systemic inflammation [2,3]. We recently
found an interaction between PD and inflammation that
further aggravates left ventricular diastolic dysfunction
(LVDD) [4]. All of these contribute to the high prevalence
of LVDD in patients undergoing PD [2,5]. Although LVDD
could be an independent prognostic marker in patients
with complex comorbidities [6], there, as yet, is scant
information on the mechanisms of the pathogenesis of
LVDD in patients undergoing PD.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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problems. One of the most undesirable effects associated
with PD is an increase in body fat mass [7,8]. Changes in
body composition, including fat distribution, in patients
undergoing PD are well described [9,10]. The distribution
of body fat plays a pivotal role in the development and
progression of both diastolic and systolic heart failure
[11]. Epicardial fat (EpF) is the true visceral fat depot of
the heart and accounts for approximately 20% of total
heart weight [12]. There are currently several methods
for evaluating EpF, including echocardiography, computed
tomography (CT), and magnetic resonance image (MRI).
Echocardiographic EpF measurement is the easiest method,
and such measurements have been proven independently
predictive of visceral adiposity and well correlated with
myocardial fat [12,13]. EpF is a source of several pro-
inflammatory and proatherogenic cytokines that influence
cardiac function [13,14]. EpF also correlates with several
cardiac comorbidities, including coronary artery disease
(CAD) and left ventricular dysfunction [15-17]. However,
there is as yet no evidence that the EpF thickness in
patients receiving PD relates to LVDD.
Therefore, the present study was performed to assess
the association between EpF and LVDD in patients under-
going PD and to clarify the relationships among EpF,
inflammation, and LVDD in this population.Material and methods
Study participants and study design
Between July 2007 and March 2009, 149 homogenous
Taiwanese patients who had undergone PD using a
conventional glucose-based lactate-buffered PD solution
(UltraBag; Baxter Healthcare SA, Singapore) for >6 months
at the specialty peritoneal dialysis clinic at the National
Taiwan University Hospital were consecutively enrolled.
Patients with hepatic disease, a history of myocardial in-
farction, coronary intervention, cardiac myopathy, or peri-
cardial disease, chronic obstructive pulmonary disease,
chronic atrial fibrillation, clinical signs of acute infection,
or other chronic inflammatory conditions were excluded,
as were patients taking statins, lipid-lowering agents, and/
or other medication that could potentially influence rele-
vant plasma parameters. All subjects underwent echocardi-
ography and abdominal CT examination. In total, 65
participants were diagnosed with LVDD as defined by our
previous reports and the recent consensus statement of the
European Society of Cardiology. In brief, LVDD was de-
fined echocardiographically by a ratio of early mitral valve
flow velocity (E) to early diastolic lengthening velocity
(e’; E/e’) during tissue Doppler imaging of ≥15 or by a com-
bination of 15 > E/e’ ≥ 8, a mitral inflow E/A ratio < 0.5,
and a deceleration time > 280 [18-20]. The remaining 84
subjects without LVDD served as the control group.Written informed consent was obtained from every
participating subject, and the study was approved by
the institutional review board of the National Taiwan
University Hospital.Biochemical data
Blood samples were collected from all patients from the
antecubital vein between 8:00 AM and 10:00 AM with the
patient in a supine position after fasting for 12 hr. No pa-
tient underwent PD exchange before sampling. Plasma
glucose and serum total cholesterol (TC), high-density
lipoprotein cholesterol (HDL), low-density lipoprotein
cholesterol (LDL), triglycerides (TG), and high-sensitivity
C-reactive protein (hsCRP) levels were determined using
an automatic analyzer (Toshiba TBA 120FR, Toshiba
Medical Systems Co., Ltd., Tokyo, Japan). All samples
were processed blindly by examiners who were unaware
of the patients’ clinical characteristics.Echocardiography and measurement of EpF
Left atrial (LA) diameter, the LV end-diastolic and systolic
diameters, interventricular septum thickness, LV posterior
wall thickness, mitral inflow early rapid filling wave (E),
peak velocity of the late filling wave due to atrial contrac-
tion (A), E/A ratio, E wave deceleration time, and mitral
annular early diastolic velocity were measured according
to the American Society of Echocardiography guidelines
using an iE33 xMATRIX echocardiography system (Philips
Healthcare, Best, the Netherlands). The LV mass index
was calculated from the LV end-diastolic and systolic
diameters, interventricular septum thickness, and LV pos-
terior wall thickness according to the method of Devereux
et al. [21]. The peak annular early and late diastolic veloci-
ties of the lateral mitral annulus during tissue Doppler
imaging (e’ and a’) were also recorded. Doppler and color
Doppler studies were performed to detect valvular heart
disease. Significant valvular heart disease was defined as at
least moderate aortic or mitral stenosis/regurgitation. EpF
was measured by 2 readers with no knowledge of the
patients’ baseline characteristics according to previously
published methods [22]. In brief, EpF was identified as the
echocardiographically free space between the outer wall of
the myocardium and the visceral layer of the pericardium,
and its thickness was measured perpendicularly to the free
wall of the right ventricle at end-systole over 3 cardiac
cycles (Figure 1). The mean value of 3 cardiac cycles from
each echocardiographic view (including both parasternal
long- and short-axis views) was recorded as the EpF thick-
ness. Repeat analysis of 20 patients was performed by
either the same or a second observer. Inter-observer
correlation coefficients were 0.89 whereas intra-observer
correlation coefficients were 0.93.
Figure 1 Echocardiographic images of a 55-year-old male patient with hypertension, dyslipidemia, and diabetes. The red area is the
epicardial fat within the pericardial sac as quantified 3-dimensionally by echocardiography.
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Each subject was imaged using a 16-MDCT scanner
(LightSpeed 16, GE Healthcare, Milwaukee, WI, USA).
The images were analyzed using image analysis software
(ImageJ, version 1.43q; National Institutes of Health,
Bethesda, MD, USA) with an attenuation range of −50
to −250 Hounsfield units to quantify the subcutaneous,
visceral, and total abdominal adipose tissue areas at the
level of the umbilicus. The results were expressed in
centimeter square. The visceral/subcutaneous adipose
tissue area ratio (V/S ratio) was calculated.
Statistical analysis
Analyses were performed using SPSS 16.0 for Windows
XP (SPSS, Inc., Chicago, IL, USA). The Kolmogorov-
Smirnov test was used to determine whether the data were
normally distributed. Data for continuous variables that
were not normally distributed were transformed using the
Napierian logarithm. Baseline characteristics and echocar-
diographic findings were compared between groups using
Student’s unpaired t test for continuous data and a chi-
squared test for categorical data. Comparisons of mean
values across groups and correlations between continuous
variables were assessed via linear regression. Odds ratios
(ORs) and 95% confidence intervals (CIs) were estimated
by logistic regression. Associations between EpF and echo-
cardiographic diastolic function parameters were deter-
mined using Pearson’s correlation coefficient. Multivariatemodels were used to assess the associations of adipose tis-
sue and serum biomarkers with LVDD. Covariates associ-
ated with LVDD, including age, diabetes, hypertension,
and the natural logarithms of the LDL level and left ven-
tricular mass index, were incorporated. All p values were




Of the 149 subjects in our sample population, 65 were
diagnosed with LVDD, and the remainder served as
controls. The baseline characteristics of the participants in
both groups are summarized in Table 1. Consistent with
previous reports on hypertension, the subjects with LVDD
were predominantly female, older, and suffered more fre-
quently from hypertension or hyperlipidemia (higher LDL
level). Patients with LVDD had significantly higher hsCRP
levels (Table 1). The cause of renal failure and the residual
renal function did not differ between the groups. Relative
to the control group, subjects with LVDD had larger end-
diastolic and systolic LV volumes (p < 0.05), greater LA
diameters, and larger indexed LV mass values (p < 0.05).
Comparison of the functional parameters showed a
prolonged deceleration time (DT) (p < 0.05), increased
mitral inflow late filling wave (p < 0.001), decreased mitral
inflow E/A ratio (p < 0.005), and decreased peak annular
early diastolic velocity of the lateral mitral annulus in
Table 1 Baseline demographic data, echocardiographic
characteristics, and adipose tissue measurements of the 149
patients undergoing peritoneal dialysis included in the study
No LVDD LVDD
Baseline characteristics (n = 84) (n = 65) p
Age (years) 53.4 ± 14.8 57.8 ± 11.7 0.035*
Women (%) 43 (51) 40 (62) 0.25
HTN (n) 50 56 <0.001*
DM (n) 23 25 0.16
Fasting plasma glucose (mg/dL) 96.2 ± 19.5 97.3 ± 11.8 0.69
HDL (mg/dL) 38.9 ± 8.3 41.7 ± 12.6 0.26
LDL (mg/dL) 83.2 ± 33.5 99.1 ± 38.0 0.05*
TG (mg/dL) 125.3 ± 85.3 142.4 ± 96.1 0.23
Height (cm) 163 ± 5.9 162 ± 6.5 0.30
Body weight (kg) 59 ± 10.5 60 ± 11.7 0.82
BMI (kg/m2) 23 ± 3.9 24 ± 3.2 0.46
CRP (mg/dL) 0.74 ± 0.99 2.13 ± 1.73 <0.001*
Primary renal diagnosis
DM 29 25 0.61
CGN 25 17 0.59
Other 30 23 0.87
Time on PD (h) 18.9 ± 1.6 19.1 ± 1.3 0.46
Kt/V 1.72 ± 0.34 1.91 ± 0.25 0.57
Residual renal function (mL/min) 1.94 ± 0.31 2.31 ± 0.22 0.25
Echocardiographic characteristics
LV end-diastolic diameter (mm) 48.4 ± 6.7 50.9 ± 7.4 0.03*
LV end-systolic diameter (mm) 30.4 ± 6.2 32.5 ± 8.1 0.04*
LA diameter (mm) 32.6 ± 6.5 37.3 ± 5.8 <0.001*
LV ejection fraction (%) 64.4 ± 7.9 66.2 ± 9.1 0.17
E (cm/s) 71.4 ± 20.0 89.4 ± 32.0 <0.001*
A (cm/s) 88.6 ± 20.2 104.8 ± 30.1 <0.001*
E/A 0.97 ± 0.46 0.77 ± 0.35 0.003*
DT (ms) 200.9 ± 45.2 238.7 ± 78.7 <0.001*
e’ (cm/s) 7.6 ± 2.4 5.7 ± 2.0 <0.001*
E/e’ 10.2 ± 4.0 17.0 ± 8.1 <0.001*
LV mass index (g/cm3) 213.4 ± 63.9 245.3 ± 77.6 0.03*
EpF (mm) 2.8 ± 1.6 5.1 ± 2.6 <0.001*
Adipose tissue distribution
Total fat (cm2) 242.7 ± 87.2 335.0 ± 207.5 0.001*
Subcutaneous fat (cm2) 123.8 ± 60.6 170.2 ± 79.3 0.001*
Visceral fat (cm2) 89.3 ± 60.4 128.1 ± 77.1 0.006*
Peritoneal fat (cm2) 52.2 ± 45.9 88.5 ± 71.2 0.003*
Retroperitoneal fat (cm2) 385.0 ± 241.5 481.3 ± 289.1 0.07
The data are presented as the mean ± standard deviation unless
otherwise indicated.
Abbreviations: LVDD left ventricular diastolic dysfunction; BMI body mass index; WC
waist circumference; DM diabetes mellitus; CGN chronic glomerular nephritis; HTN
hypertension; HOMA homeostasis model of insulin resistance; CRP C-reactive
protein; LDL low density lipoprotein; HDL high density lipoprotein; TG triglyceride;
PD peritoneal dialysis; kt/v, k = dialyzer clearance of urea, t = dialysis time,
v = volume of distribution of urea, approximately equal to the patient’s total body
water; LA left atrial; LV left ventricular; E mitral inflow E wave; A mitral inflow A
wave; DT mitral inflow deceleration time; e’, peak annular early diastolic velocity of
the lateral mitral annulus in tissue Doppler imaging; IVRT interventricular relaxation
time; EpF epicardial fat. *, p < 0.05.
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with LVDD.
Comparison of the anthropometric characteristics sho-
wed higher levels of markers reflecting fat distribution, such
as the amounts of total, subcutaneous, visceral, and peri-
toneal fat (p < 0.001, p < 0.001, p < 0.01, and p < 0.005,
respectively), in the LVDD group.
Correlation between EpF thickness and LVDD
The bivariate Pearson correlation coefficients for LV dia-
stolic function parameters and EpF are shown in Figure 2.
EpF was significantly associated with tissue Doppler e’, E/e’,
and DT (r = −0.39, p < 0.001; r = 0.27, p = 0.001; r = 0.29,
p < 0.001, respectively) (Figure 2A–C). EpF thickness was
greater in patients with LVDD (n = 65; 5.1 ± 2.6 mm) than
in controls (n = 84; 2.8 ± 1.6 mm, p < 0.001, Figure 2D).
Factors associated with LVDD
We performed univariate analysis to determine the risk
factors associated with the development of LVDD. Hyper-
tension, the natural logarithm of the LDL level [Ln(LDL)],
Ln(Visceral fat), Ln(Peritoneal fat), the hsCRP level, Ln(LV
mass index) and EpF thickness were significantly associ-
ated with the presence of LVDD (Table 2).
Accumulation of EpF rather than visceral fat is an
independent risk factor for LVDD
We previously found subclinical inflammation (e.g., the
plasma hsCRP level) to be an independent risk factor for
LVDD in patients with metabolic syndromes [4]. We
therefore performed multivariate analysis of the risk fac-
tors other than adiposity that were associated with LVDD
in our univariate analyses and found that the hsCRP level
remained associated with LVDD after adjustment for age,
gender, diabetes mellitus, hypertension, the hsCRP and
LDL levels, and the LV mass index (OR: 1.75, 95% CI:
1.08–3.12, p = 0.038; Table 3, model 1).
We further evaluated fat distribution and its associ-
ation with LVDD by multivariate regression analysis. Of
the CT measures of fat distribution, Ln(visceral fat) and
Ln(peritoneal fat) remained associated with LVDD after
adjustment for the abovementioned confounding factors
(adjusted OR = 2.29, 95% CI = 1.06–5.57, p = 0.013 and
adjusted OR = 2.45, 95% CI = 1.1–5.9, p = 0.011 respect-
ively; Table 3, models 2–3). We repeated the multivariate
analysis with adjustment for the hsCRP level and found
that this abolished the associations of visceral and peri-
toneal fat with LVDD. The effect of the hsCRP level itself
remained significant in both models (OR = 2.56, 95% CI =
1.08–4.72, p = 0.023 and OR = 2.70, 95% CI = 1.21–6.69,
p = 0.019, respectively; Table 3, model 4 and model 5),
indicating that hsCRP might mediate the effect of visceral
and/or peritoneal fat on LVDD. To elucidate the influence
of EpF, we adjusted for all of the confounding factors and
Figure 2 Correlation between epicardial fat (EpF) thickness and left ventricular diastolic dysfunction (LVDD). EpF thickness
correlated significantly with (A) e’ (r = −0.39, p < 0.001), (B) E/e’ (r = 0.27, p < 0.001), and (C) mitral inflow deceleration time
(r = 0.29, p = 0.002). (D) EpF thickness in patients with or without left ventricular diastolic dysfunction (LVDD). The bar graph
shows the mean + standard deviation. EpF thickness was significantly greater in patients with LVDD (5.1 ± 2.6 cm3) than in controls
(2.8 ± 1.6 cm3, p < 0.001).
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in model 6. EpF remained an independent, significant
predictor of the presence of LVDD in this model, which
may imply that EpF influences LV diastolic function
through pathways other than subclinical inflammation.Table 2 Univariate logistic regression analyses of risk
factors associated with the presence of LVDD
OR (95% CI) p
Age 1.02 (0.99–1.04) 0.14
Gender 1.53 (0.80–2.94) 0.21
BMI 1.05 (0.92–1.20) 0.45
DM 1.66 (0.83–3.31) 0.15
Hypertension 4.11 (1.80–9.42) <0.001
Ln(LDL) 3.38 (1.01–11.36) 0.049
Ln(TG) 0.95 (0.48–1.88) 0.88
Ln(Visceral fat) 2.09 (1.18–3.68) 0.01
Ln(Peritoneal fat) 1.92 (1.22–3.02) 0.005
hsCRP 2.09 (1.56–2.79) <0.001
Ln(LV mass index) 4.98 (1.10–22.64) 0.03
EpF 1.75 (1.41–2.17) <0.001
Abbreviations: LVDD, left ventricular diastolic dysfunction; OR, odds
ratio; CI, confidence interval; BMI, body mass index; DM, diabetes
mellitus; Ln(LDL), natural logarithm of low-density lipoprotein; TG,
triglyceride; hsCRP, high-sensitivity C-reactive protein; LV, left
ventricular; EpF, epicardial fat. ORs and 95% CIs were estimated by
logistic regression.Discussion
In this study, we found that EpF thickness in patients
undergoing PD patients correlates with LVDD even after
adjustment for all of the confounding factors, whereas
visceral fat was not significantly independently associ-
ated with LVDD. In addition, LVDD was significantly
associated with the hsCRP level in this specific group of
patients. Inflammation and EpF were the 2 most import-
ant risk factors for LVDD, implying that these factors
might act synergistically.
Although there is no published figure for the preva-
lence of diastolic heart failure in patients undergoing
PD, LV diastolic heart failure would be expected more
frequently among patients with ESRD than in the gen-
eral population due to the inflammation, fluid overload,
hypertension, renin-angiotensin-aldosterone system acti-
vation, and LV hypertrophy associated with ESRD [2,23].
Abnormal fat distribution seems a likely culprit for the
high prevalence of LVDD in patients undergoing PD.
Such patients tend to have elevated amounts of intra-
abdominal fat [24], and we recently found higher
amounts of visceral adipose tissue to be associated with
low-grade inflammation, which leads in turn to subclin-
ical LVDD [4]. However, the current study is to the best
of our knowledge the first report that inflammation and
EpF content are independent risk factors for LVDD in
patients with PD and thus suggests some explanations
for the prevalence of LVDD in this group. EpF is
Table 3 Multivariate logistic regression models for
parameters associated with left ventricular diastolic
dysfunction
Odds ratio 95% Confidence interval p
Model 1
Age 1.07 1.01–1.14 0.018*
Ln(LV mass index) 14.88 1.91–115.7 0.01*
DM 1.60 0 50–5.12 0.425
HTN 2.18 0.48–9.93 0.313
Ln(LDL) 5.54 1.31–23.52 0.02*
hsCRP 1.75 1.08–3.12 0.038*
Model 2
Ln(Visceral Fat) 2.29 1.06–5.57 0.013*
Model 3
Ln(Peritoneal Fat) 2.45 1.1–5.92 0.011*
Model 4
Ln(Visceral Fat) 2.10 0.85–6.43 0.344
hsCRP 2.56 1.08–4.72 0.023*
Model 5
Ln(Peritoneal Fat) 2.23 0.85–6.78 0.268
hsCRP 2.23 1.21–6.69 0.019*
Model 6
EpF 2.41 1.43–4.08 0.01*
Ln(visceral Fat) 2.04 0.48–6.68 0.14
Peritoneal Fat 3.15 0.12–8.65 0.50
hsCRP 3.03 1.26–7.30 0.01*
Abbreviations: Ln(LV mass index), natural logarithm of the left
ventricular mass index; DM, diabetes mellitus; HTN, hypertension; hsCRP,
high-sensitivity C-reactive protein; LDL, low-density lipoprotein; EpF,
epicardial fat. Odds ratios and 95% confidence intervals were estimated
by logistic regression. Models 2–6 adjust for age, DM, HTN, Ln(LDL),
and Ln(LV mass index). Model 4 and model 5 additionally adjust for
hsCRP. Model 6 additionally adjusts for hsCRP and adiposity
components. *, p < 0.05.
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(FFA) [25], which encounter no physical barrier or fascia
before reaching the cardiomyocytes [26]; therefore, the
myocardium receives a double dose of FFA from both
the EpF and the systemic circulation.
There are also hypothesis that EpF can influence LV
diastolic function. EpF is a source of several bioactive
molecules that might directly influence the myocardium
[27]. In metabolic and cardiovascular disease states,
these fat tissues expand, becoming hypoxic and dysfunc-
tional [28,29] and recruiting phagocytic cells [30] which
would lead to reducing the production of protective
cytokines, increasing detrimental adipocytokines and
impaired cardiac function eventually. Besides, Iozzo P
et al. have documented that the entire mass of fat
surrounding the heart ranges on average from 100 g
(healthy individual) to 400 g (type II DM patient),extending to 800 ~ 900 g in some patients [31]. This
weight probably poses a mechanical burden on cardiac
expansion, and may further deteriorate LVDD in PD
patients. The diagram for the above discussion is summa-
rized in Additional file 1.
Increased levels of myocardial triglycerides could cause
cardiomyocyte apoptosis, increased oxidative stress, and
impairment of cardiac function. Kankaanpää et al. evalu-
ated EpF and left ventricular (LV) function using MRI
and concluded that FFA exposure and EpF may increase
accumulation of myocardial triglycerides, which might
have negative effect for LV overload and hypertrophy
[32]. A recent study assessing the association between
echocardiographic EpF and myocardial fat found that
echocardiographic EpF accumulation might reflect myo-
cardial fat in subjects with a wide range of adiposity
[22]. Taken together, the current study and previous evi-
dence suggest that the mechanisms delineated in animal
models also operate in patients undergoing PD. These
patients have abnormal fat distribution, and accumula-
tion of fat, especially visceral fat, can potently exacerbate
inflammation. In addition, recent studies show that epi-
cardial adipose tissue plays an important role of develop-
ment and progression of CAD. Elevated inflammatory
infiltrate has been described in EpF of subjects with
CAD [33]. When compared with subcutaneous fat, in-
flammatory cell infiltration, mainly contributed by mac-
rophages, is enhanced in epicardial adipose tissue
[33,34]. Besides of macrophage accumulation, macro-
phage phenotypic change in epicardial adipose tissue of
CAD patients is also demonstrated [35]. Moreover, as
we look into the role of visceral fat in the pathogenesis
of CAD, there is evidence which suggests that not only
EpF but mediastinal adipose tissue contributes locally to
the development of coronary atherosclerosis via gluco-
corticoid action [36]. Increased epicardial fat thickness is
shown to be an independent risk factor for CAD in spe-
cific patients [37], and there are probably gender dispar-
ities in the association between epicardial adipose tissue
volume and CAD [38].
In our current study, we measured the amount of EpF
by echocardiography. Malavazos et al. [22] documented
that echocardiographic measurement accurately esti-
mates the actual amount of EpF, which could be a strong
and independent predictor of myocardial fat (repre-
sented by triglycerides stored within the cardiac muscle
tissue). Echocardiographic EpF measurement has advan-
tages for use in both clinical and research settings, in-
cluding low cost, routine applicability, avoidance of
exposure to radiation, and potential for monitoring
therapeutic effects. As myocardial fat has progressive
and harmful effects on LV diastolic function, accumula-
tion of EpF may affect the heart as well [39]. Atrial en-
largement has been shown to correlate with impairment
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current study, we controlled for the influence of sys-
temic adiposity and its effect via systemic inflammation
and still found an independent role for the amount of
EpF in the development of LVDD. These results not only
reveal that EpF directly reflects myocardial fat content
but also allow us to monitor early myocardial changes in
patients undergoing PD. This convenient method might
even be able to detect the development of LVDD, allowing
early initiation of treatment and monitoring of the re-
sponse of therapy, which is especially important in pa-
tients with multiple co-morbidities.
An elevated or excessive amount of adipose tissue is
regarded as a risk factor for a number of diseases, includ-
ing insulin resistance, type 2 diabetes mellitus, and athero-
sclerosis, all of which can lead to major cardiovascular
sequelae. Further, adipose tissue is associated with changes
in both inflammatory cells and biochemical markers of in-
flammation [23,41]. In the current study, we demonstrated
that inflammation and accumulation of EpF play pivotal
roles in the development of LVDD in patients undergoing
PD. However, the associations therewith of visceral and
peritoneal adipose tissue were no longer significant after
adjustment for inflammation. We recently assessed the
role of pro-inflammatory cytokines in the relationship
between inflammation and LVDD in patients undergoing
PD [42]. That study identified a significant correlation
between LVDD and serum markers of inflammation in pa-
tients undergoing PD and an interaction between PD and
inflammation. Taking these results together with the find-
ings of the current study, we speculate that the systemic
load of adipose tissue in patients undergoing PD might in-
crease the susceptibility to LVDD through inflammation,
while EpF represents the true amount of myocardial fat
and thus acts independently. Inflammation (contributed in
part by systemic adipose tissue) and increase of triglycer-
ides stored within the cardiac muscle tissue (proportional
to EpF) could therefore act synergistically to cause LVDD.
Our study had several limitations. First, we used cross-
sectional data to infer longitudinal relationships. Although
a model was identified, additional associations and pos-
sible pathways may exist, and further, prospective studies
will be necessary to delineate a precise causal relationship.
Second, all of the patients in our current study are Taiwan-
ese. The generalizability to other population should be
demonstrated by further study. Third, the effects of LVDD
and EpF thickness on the long-term outcomes of patients
undergoing PD warrant further investigation.
In conclusion, we delineated for the first time the com-
plex relationships among EpF accumulation, inflamma-
tion, and LVDD in patients undergoing PD. This study
demonstrated that the amount of EpF but not visceral adi-
pose tissue is independently associated with subclinical
LVDD in patients undergoing PD.Additional file
Additional file 1: The diagram for the hypothesis of how epicardial
fat influence left ventircular diastolic function.
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